Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC)

Qianqian Zhu; Hong Ge; Jie Ma; Xiao Liu; Ke Ye; Jinming Yu; Daoke Yang; Chengliang Yang; Yanan Sun; Yingying Cui

doi:10.18632/oncotarget.14515

Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC)

Qianqian Zhu(Qingdao University), Hong Ge(Zhengzhou University), Jie Ma(Zhengzhou University), Xiao Liu(BGI Group (China)), Ke Ye(Zhengzhou University), Jinming Yu(Shandong University), Daoke Yang(First Affiliated Hospital of Zhengzhou University), Chengliang Yang(Liaoning Cancer Hospital & Institute), Yanan Sun(Zhengzhou University), Yingying Cui(First Affiliated Hospital of Zhengzhou University)

Oncotarget

January 5, 2017

10.18632/oncotarget.14515

Cited by 46

|The Lancet|2022|900

Investigation on microstructure and mechanical properties of Al-Zn-Mg-Cu alloys with various Zn/Mg ratios

|Journal of Material Science and Technology|2021|338

3D printing with cellulose materials

|Cellulose|2018|313

Curcumin Blocks Small Cell Lung Cancer Cells Migration, Invasion, Angiogenesis, Cell Cycle and Neoplasia through Janus Kinase-STAT3 Signalling Pathway

|PLoS ONE|2012|219

Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis

|Cell Metabolism|2022|208

Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC)

Related Papers